Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RABIMO: Ranibizumab Dosing Regimens in AMD
NCT01831947Phase 4Completed
- Sponsor
- Institut für anwendungsorientierte Forschung und klinische Studien
- Start
- Apr 2010
- Primary completion
- Mar 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Institut für anwendungsorientierte Forschung und klinische Studien. Started Apr 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01831947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01831947.